A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...
Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing ...
By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...
Pfizer made one thing clear this week: It's officially back in the obesity race.
Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up ...
Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) ...
Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...
Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.
Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed ...
Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a ...
WASHINGTON -- Pfizer announced Friday that it submitted a request to the U.S. Food and Drug Administration to allow emergency use of its COVID-19 vaccine to children as young as 12. This is the next ...
The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...